PubMed ID: 39642160 Author(s): Qiu X, Gammon ST, Rasmussen C, Pisaneschi F, Kim CBY, Ver Hoeve J, Millward SW, Barnett EM, Nork TM, Kaufman PL, Piwnica-Worms D. In vivo scanning laser fundus and high-resolution OCT …
Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications.
PubMed ID: 39845838 Author(s): Ebrahimi M, Ahmadieh H, Rezaei Kanavi M, Safi S, Alipour-Parsa S, Advani S, Sorenson CM, Sheibani N. Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications. Front Med (Lausanne). 2025 …
Choroidal Mast Cells and Pathophysiology of Age-Related Macular Degeneration.
PubMed ID: 38201254 Author(s): Malih S, Song YS, Sorenson CM, Sheibani N. Choroidal Mast Cells and Pathophysiology of Age-Related Macular Degeneration. Cells. 2023 Dec 26;13(1):50. doi: 10.3390/cells13010050. PMID 38201254 Journal: Cells, Volume 13, Issue 1, …
NEXPEDE-1
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1).
KOWA 303
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
KOWA 301
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
AURA 301
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Intermediate Lesions or Small Choroidal Melanoma.
NAC Attack
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double-Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa.
UNI-RARE
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants.